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Mechanism of Action of Toxic Halogenated
Aromatics
by Alison E. M. Vickers,* Tracy C. Sloop* and George W.
Lucier*
2,3,7,8-TItrachlorodibenzo-p-dioxin (TCDD) and related halogenated aromatic hydrocarbons are a highly
toxic class of environmental contaminants, as evidenced by numerous cases of accidental poisonings of
human and animal populations and their extreme toxic potency in laboratory animals. The proposed model
forthe mechanism ofaction ofTCDD andrelated compounds is analogous tothatofthe stereoid hormones,
which modulate gene expression through a receptor mechanism. In the steroid receptor model, the
compound enters the cell cytoplasm where it acts as a specific ligand, binding selectively to a high affinity
receptor protein. Bound to the appropriate ligand, the receptor concentrates in the nucleus where its
increased association with chromatin leads to altered gene expression. This model has been useful in
characterizing the Ah receptor; however, it does not provide a unifying hypothesis for all biochemical and
toxic effects associated with exposure to halogenated aromatic hydrocarbons. Several findings suggest that
a primary factor in determining TCDD toxicity might be tissue and species specific factors that control the
actions of Ah receptor(s) in target tissues. Furthermore, numerous mechanisms might be involved.
Clarifying the mechanism(s) for TCDD toxicity would enhance our ability to predict human health
consequences to toxic halogenated aromatic hydrocarbons and would provide a more rational basis forrisk
analysis.
Introduction
2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) has re-
ceived a great deal of attention in recent years over a
growing concern that its presence in the environment
may pose a potential human health hazard. This
compound and other chlorinated dibenzo-p-dioxins,
dibenzofurans, azo(xy)benzenes, naphthalenes and bi-
phenyls belong to a class of structurally related
chemicals known as the halogenated aromatic hydro-
carbons, some of which produce similar patterns of
toxicity and biochemical responses and are believed to
act through a common mechanism (1-4). Many of the
halogenated aromatic hydrocarbons are contaminants in
commercial products and have become widespread in
the environment where their chemical stability, re-
sistance to degradation and lipophilic properties have
led to their concentration inthe food chain. TCDD isthe
most potent chemical of this class and is presently one
of the most toxic synthetic compounds known (5).
TCDD is also the most extensively studied of the
halogenated aromatic hydrocarbons and has therefore
become a prototype forthis class oftoxic environmental
contaminants.
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TCDD can be formed as a by-product in the synthesis
of2,4,5-trichlorophenol from 1,2,4,5-tetrachlorobenzene
and therefore may occur as a contaminant of the
herbicide 2,4,5-trichlorophenoxyacetic acid and ofother
products which utilize chlorophenols or chlorobenzenes
in their synthesis (2,6,7). Chlorinated dioxins have also
been discovered in fly ash from municipal and industrial
incinerators, an apparent result ofincomplete combus-
tion of organic chlorinated compounds (8,9).
Several industrial accidents as well as incidents
involvingimproperdisposalofwasteresiduescontaining
TCDD have resulted in accidental poisonings of human
and animal populations (10-14). Workers involved in the
manufacture of 2,4,5-trichlorophenol have experienced
a wide variety of health effects including chloracne,
hepatic dysfunction, peripheral neuritis, disorders of
fat metabolism and porphyria cutanea tarda (6). An
increased incidence of soft-tissue sarcoma may also
occur in these men as well as a group of Swedish men
exposedtophenoxyherbicides andchlorophenols during
their application (15,16). The increasing potential for
widespread exposure of man via industrial accidents
and careless dumpingofchlorinated dioxins hasprompt-
ed research into their toxicity. Presently researchers
are unable to estimate man's relative sensitivity to
TCDD and the level of exposure which will produce
toxicity.VICKERS, SLOOP AND LUCIER
Toxicity
While investigations with laboratory animals have
established TCDD as an extremely potent toxin and
teratogen (5,17), the mechanism oftoxicity has not been
determined. In laboratory animals TCDD produces a
multitude oftoxic responses. The most consistent toxic
response to TCDD in all species studied are thymic
atrophy and loss in body weight (18). The reproductive
capabilities of most species is drastically reduced
apparently reflecting effects on seminiferous tubules
(19,20). The hyperplastic responses induced by TCDD
exposure predominantly affect epithelialtissues: gastric
mucosa (21,22), bladder (23,24) and skin (18), and these
responses may be related to a carcinogenic activity of
TCDD. Rodent studies implicate TCDD as a potent
promoter of rat hepatocellular carcinomas (25) and
mouse skin tumors (26). The wide spectrum of toxic
responses to TCDD makes it difficult to specify the
organ or the biochemical mechanism responsible for
lethality. Tissues can be classified as responding to
TCDD in an atrophic or hyperplastic response with the
exception of the liver in which both hyperplasia and
necrosis are observed. The impact of TCDD exposure
onindividual organs differs amongspecies andpresently
cannot be explained (Table 1).
An enigma ofTCDD is the tremendous difference in
toxicity observed amonganimalspecies. The acute LD50
of TCDD varies over a 5000-fold range, guinea pig (5)
being the most sensitive species, followed by rat,
monkey, rabbit, mouse, dog, and hamster as the least
sensitive species (27,28) (Table 1). A similar range
(103-104 difference) in toxicity is observed for such
closely related TCDD isomers as 2,3,7,8,- and 1,2,3,8-
TCDD (29,30) (Table 2). In general, all of the highly
toxic halogenated dibenzo-p-dioxins showboth the same
order ofspecies' sensitivity and elicit similar patterns of
toxic responses within a given species when adminis-
tered at a sufficient dose.
An absence of convincing evidence that TCDD is
mutagenic (31) orthat it binds covalently to DNA to any
appreciable extent (32-34) suggests thatTCDD isnot an
initiator of carcinogenesis and genetic toxicity is not
involved in the mechanism of action. There is more
supportive evidence, however, that TCDD may act as a
tumor promoter (35,36). Using a two-stage model of
hepatocarcinogenesis, Pitot et al. (37), demonstrated
that chronic dietary administration ofTCDD following a
Table 1. Tbxic effects of TCDD in various species.'
LD50, Liver Weight Thymic
Species ,ug/kg damage loss Chloracne atrophy
Guinea pig 0.6-1 - + - +
Monkey -70 + + + + +
Rat 25-60 + + + - +
Rabbit 100 + + + + + +
Mouse 200-600 + + - +
Hamster 5500 + + - +
aData summarized from Poland (27) and Gasiewicz (28).
single low dose of diethylnitrosamine resulted in
increased enzyme altered foci and hepatocellular car-
cinomas within 28 weeks. Using this model, TCDD
administration resulted in a higher incidence of cancer
in a shorter time when compared to chronic feeding
studies where carcinomas were observed at 104 weeks
in rats and mice (38). In the chronic feeding studies it is
hypothesized that tumors arise from TCDD promoting
action on background initiated cells.
TCDD congeners including 1,2,3,6,7,8-hexachloro-
and 1,2,3,7,8,9-hexachlorodibenzodioxin were found to
increase the incidence of hepatocellular carcinomas in
chronic feeding studies while 2,7-dichlorodibenzodioxin
and dibenzodioxin were void of carcinogenic activity in
either sex of rats or mice (39,40). Hepatocellular
carcinoma has also been observed in mice following
exposure to the related halogenated aromatics, poly-
brominated and polychlorinated biphenyls (41-43). Like
TCDD, polychlorinated biphenyls are tumor promoters
in the rat two-stage model ofhepatocarcinogenesis (44).
The mechanism for tumor promoting activity of TCDD
and related compounds is unclear, although there is
considerable evidence that the toxicity of TCDD and
related halogenated aromatics is mediated through the
specific binding to a cytosolic receptor. A mechanism of
tumor promotion may involve such a cytosolic receptor.
Metabolism
The tremendous variation in species sensitivity to
TCDD and related compounds cannot be explained by
differences in metabolic rate, clearance times, body
burden ofthe compounds, or by macromolecular adduct
formation. TCDD appears to be poorly metabolized as
evidenced by whole body halflife times of22-42 days in
the guinea pig, 23-31 days in the rat, and 10-12 days in
the hamster (45). Elimination of TCDD is a first order
process in most species. Polar metabolites are formed
slowly and excreted in the urine and bile comprising
15% of an administered dose in the rat at 21 days (46).
The major route ofelimination ofunmetabolized TCDD
is viathefeces, which comprises 53% ofan administered
dose in the rat. In contrast to the general elimination
order for most species, the hamster excreted the
greatest percentage (41%) of an administered TCDD
dose by way of the urine (47).
Table 2. Tbxic potency (LD50) of various polychlorinated
dibenzodioxins.'
Tbxic potency (LD50), ,ug/kg
Guinea
Chlorination pig Rat Dog Monkey
2,3,7,8 (TCDD) - - 1,000 2
1,2,3,4 - 800 - -
2,4,8 - 5,000 - -
2,3,7 29,400 - - -
2,8 300,000 - - -
1,2,4,7,8 1,125 - - -
1,2,3,4,6,7,8,9 - 1,000 - -
aData from Bickel (30).
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The primary storage sites for unmetabolized TCDD
are the liver and adipose tissue (46). Studies with rats,
guinea pigs, hamsters, and mice have confirmed liver as
the primary site ofTCDD distribution with radiolabeled-
TCDD levels reaching 50 times that of other tissues
(45). The in vivo hepatic uptake of radiolabeled TCDD
was found to be greater in the mouse strain characteristi-
cally responsive to TCDD, C57BL/6J, attaining levels
twice that ofthe nonresponsive strain, DBA/2J (48,49).
However, the whole body half-life was greater in the
nonresponsive strain: 24 days compared to 11 days inthe
responsive strain(49). Thelipophilicityandlowpotential
for biotransformation of such halogenated aromatic
hydrocarbons leads to their distribution and long-term
storage in adipose tissue and skin (50). TCDD distribu-
tion differences were also evident in adipose tissue. The
DBA strain attained adipose tissue concentrations twice
that of the C57 strain. Differences in pharmacokinetic
processes among species may play a role in the
biochemical effects ofTCDD, however, only a threefold
difference in clearance times exist between hamsters
and guinea pigs, which is not sufficient to explain the
5000-fold difference in LD50 observed between these
two species.
Although liver is the primary site ofTCDD distribu-
tion and accounts for 16-43% of an administered dose,
tremendous differences in hepatotoxicity are observed.
For example, hepatotoxicity is observed in the guinea
pig (51) and rat (52) following doses of 2 to 400 ,ug
TCDD/kg, while the hamster is resistant, even when
hepatic TCDD concentrations are several orders of
magnitude greater (53). These differences cannot be
attributed to metabolic activation of TCDD since
virtually all ofthe radioactivity remaining in the liverin
these species is parent compound and extractable
(>99%) (54).
Enzyme Induction
TCDD is considered a 3-methylcholanthrene (3-MC)
-type inducer because ofitsability toinduce cytochrome
P1-450 and its associated aryl hydrocarbon hydroxylase
(AHH) activity (55,56) and to suppress such enzymes as
benzphetamine N-demethylase (57) and uropor-
phyrinogen decarboxylase (58). The inductive and
suppressive actions of TCDD might be modulated
through a cytosolic receptor or by TCDD itself.
Suppression ofdrug-metabolizing enzymes has notbeen
observed in any extrahepatic tissues studied and may
be organ specific.
The accumulation of high levels of unmetabolized
TCDDintheliverisassociatedwithnumerousbiochemi-
cal and ultrastructural effects, some of which may
reflect an adaptive response by the liver such that
increasing concentrations ofTCDD in the liver induces
enzymes which in turn may facilitate its biotransforma-
tion and excretion. The proliferation of the hepatic
smooth endoplasmic reticulum and induction of several
drug metabolizing enzymes, including several forms of
cytochrome P450 (59,60), UDP-glucuronyltransferase
(61) and glutathione-S-transferase (62) could represent
such a response. However, the exact pathways involved
in TCDD metabolism have not yet been characterized.
In turn, induction of enzymes, such as ornithine
decarboxylase by TCDD represent trophic responses
and occur during times of hyperplasia (63).
The most studied response elicited by TCDD and its
congeners is the induction of the hepatic microsomal
enzyme aryl hydrocarbon hydroxylase (56). Inducibility
ofcytochrome P1-450 and its associated AHH activity is
genetically regulated by a single locus, the Ah locus
(64-67). Studies based on genetic crosses and back
crosses between C57BL/6, the prototype strain res-
ponsive to 3-MC induction of cytochrome P1-450 and
AHH activity, and DBA/2, the prototype nonresponsive
strain, demonstrated that theAh locus controls expres-
sion ofa battery ofgenes, including cytochrome P1-450,
and AHH activity. Essential to the induction process is
the existence of a cytosolic Ah receptor which binds
TCDD and related halogenated aromatics. Thisreceptor
appears to control the coordinate expression of the
battery ofenzymes regulated by the Ah locus. To date,
TCDD is the most potent ligand for this receptor, being
30,000 x more potent than 3-MC for induction of
cytochrome P1-450 and AHH activity in vivo (68,69).
The lack ofsensitivity to AHH inducers observed in the
nonresponsive strain has been attributed to a mutation
in these mice which produces an Ah receptor with a
markedly diminished affinity for AHH-inducing com-
pounds (68-72). The capacity of TCDD-receptor inter-
actions to modulate enzyme activity varies with the
tissue, as observed by the hyperplastic response in
epithelial tissue and atrophic response in thymic tissue.
Polymorphism in the Ah locus is also observed among
animal species. For example, TCDD and 3-MC induce
aldehyde dehydrogenase in the rat liver but not mouse.
However, both compounds induce hepatic DT-diaphorase
in rat and mouse but not guinea pig (73).
The results of numerous structure activity studies
demonstrate an excellent correlation between the rank
order of binding to the cytosolic Ah receptor with the
induction of AHH and cytochrome P1-450 in chick
embryo liver and rat hepatoma cells (74-78), the
induction of UDP-glucuronyltransferase, ornithine de-
carboxylase, DT-diaphorase in mice (62, 79,80); ability
to produce lethality in guinea pigs, mice, and chick
embryos (81-83), thymic atrophy and teratogenicity in
mice (56,84,85), chloracne in hairless mice and rabbits
(86) as well as keratinization in XB cells (87). These
studies are important in establishing the relationship
between congener structure, receptor binding and
toxicity. The induction of several enzymes and toxic
responses appear to be mediated through a genetically
controlled receptor(s) that exhibits binding affinities
dependent on structure oftoxic halogenated aromatics.
TCDD congeners which are tetra-, penta-, and hexa-
isomers halogenated in the 2,3,7,8-positions demon-
strate the maximal potency for induction of AHH
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activity and toxicity. Structure-activity studies have
demonstrated the importance ofthe 2,3,7,8-positions in
induction of AHH in rat hepatoma cells (88).
Properties of TCDD Receptor
2,3,7,8-TCDD is presently the most useful ligand for
Ahreceptordetectionandquantitation. TheAhreceptor
is an anomaly in that its structure and mechanism is
analogous to known steroid receptors; however, no
known steroid or endogenous compound is a ligand for
the receptor. The Ah receptor is present in the cytosol
withthe liverand lungcontainingthe highestproportion
of receptor in guinea pig, hamster, rat, and mouse
(29,89) (Table 3). High levels ofreceptor exist in thymic
tissue ofguinea pigand rat. Low levels were detected in
mice and hamster. Most other tissues examined contain
low or undetectable levels ofreceptor except for guinea
pig testes, which exhibited levels comparable to liver
values. Variations in receptor numbers and affinity for
ligand may play a role in the pleiotropic sensitivity of
the tissue and species. For example, the sensitivity to
thymic atrophy in the rat and guinea pig may be
explained by the existence ofreceptor levels eight times
those observed in the less sensitive mouse or hamster
(53,90).
TheAh receptor has been most notably characterized
inhepatic tissues. Literature valuesforhepaticreceptor
concentrations of guinea pig, rat, monkey, mouse and
hamster range from 23 to 74 fmole/mg cytosolic protein
and exhibit a reversible high affinity binding for TCDD,
Kd 0.1 to 0.4 nM (28). This binding is competed for by
2,3,7,8-tetrachlorodibenzofuran, 3-methylcholanthrene,
benzo(a)pyrene and ,-naphthoflavone-all inducers of
AHH activity-and is not competed for by inducers of
other forms of cytochrome P-450 such as phenobarbital
or 16a-cyanopregnenolone (91), or the steroids, dexa-
methasone, progesterone, estradiol, testosterone, and
2-hydroxyestradiol (75). Qualitatively, the hepatic cyto-
solic Ah receptor has markedly similar properties
among the species examined. The receptor displays a
5S sedimentation coefficient on sucrose density grad-
ients, a stokes radius of 6.6 nm and a molecular weight
of136,000 in rat livercytosol. The receptoris heat labile
and inactivated by trypsin (92).
The ontogeny of the Ah receptor has been studied in
hepatic tissues of rat, mouse, and rabbit (93,94).
Receptor levels increased postpartum, reaching maxi-
mum levels by 21 days and decliningthrough adulthood.
Peak receptor levels at 21 days corresponded with
maximal AHH induction. Receptor levels in the lung
paralled the postpartum increase seen in the liver with
maximum levels exhibited at day 15. In the thymus,
receptor levels remained relatively constant throughout
the 42 day studywith levels attaininghalfthe maximum
levels observed in the liver and lung. Hepatic receptor
concentrations are notsignificantly altered byorchiecto-
my, ovariectomy, adrenalectomy or, hypophysectomy
(95).
Several studies have attempted to investigate nuclear
uptake and binding of TCDD and related halogens and
the role that cytosolic and/or nuclear receptors play in
this process. There are some indications that the Ah
receptor is primarily nuclear (96), and the cytosolic
receptor represents, in part, artifacts arising during
subcellular fractionation. Nevertheless, the nuclear
translocation process may be important.
The intranuclear binding ofTCDD has been detected
in the liver, lung, thymus, and kidney of C57BL/6J and
DBA/2J mice (97,98) Sprague-Dawley rats (98,99) and
cultured hepatoma cells (100). Translocation of the Ah
receptor from the cytoplasm is neither temperature-
sensitive nor does it require an activation step, in
contrast to known steroid receptor systems (101).
Following injection of rats with radiolabeled TCDD,
maximum nuclear uptake was observed simultaneously
with a decline in cytosolic radioactivity at 2 hr in the
liver and 3 hr in thymus (99,102). TCDD does not bind
DNA unless it is bound to receptor and the inductive/re-
pressed cellular responses appear to require nuclear
binding (97,101). The nuclear binding component is
similar to the cytoplasmic entity in that it is saturable,
heat labile, sensitive to proteolysis, displays an equili-
brium dissociation constant of 1.05 nm and sediments in
the 4 to 5S region on sucrose density gradients (102).
Nuclear Ah receptor concentrations range from 8 to 16
fmole/mgnuclear protein for liver, lung and kidney in the
C57BL/6J mice and Sprague-Dawley rats. Following
equivalent doses of TCDD, nuclear Ah receptor con-
centrations for liver, lung and kidney in the non-
responsive DBA/2J mice were two- to three-fold lower
than those in the responsive C57BL/6J strain (98).
Table 3. Concentrations and dissociation constants (Kd) of cytosolic receptor from various species and tissues.a
Liver Thymus
Concn, Conen,
Species fmole/mg protein Kd, nM fmole/mg protein Kd, nM
Guinea pig 59 ± 11 0.06 ± 0.01 47 ± 7 0.10 ± 0.07
Rat 61 ± 23 0.12 ± 0.03 138 ± 15 0.12 ± 0.05
Mouse
C57BL/6J 74 ± 10 0.29 ± 0.01 24 ± 2 0.27 ± 0.03
B6DZF1/J 23 ± 2 0.42 ± 0.03 9 0.35
DBA/2J ND ND ND ND
Hamster 67 ± 22 0.33 ± 0.07 5 ± 6 0.24 ± 0.08
aData summarized from Gasiewicz (28).
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TCDD is the only known ligand capable of triggering
translocation of the "defective" Ah receptor in DBA/2J
mice and which is sufficient to evoke a response,
induction of cytochrome P1-450. Translocation of the
TCDD-receptor complex from the cytoplasm to the
nucleus may vary with the tissue. For example the liver
and thymus contain equivalent amounts of cytoplasmic
receptor, but nuclear uptake by the thymus of TCDD-
receptor complexes following in vivo exposure is only
6% of that observed in the liver (99).
Despite large differences in species toxicity and an
inability to relate tissue Ah receptor levels to toxicity,
all species examined possess marked similarities in the
receptor properties, tissue distribution and ontogeny of
the Ah receptor. The functional aspect ofthis receptor,
the reason for its conservation among species and the
properties and function ofa possible endogenous ligand
are as yet unknown. The functional capacity, however, of
the Ah receptor is dramatically different when compar-
ing the liver and thymus. Following exposure to TCDD,
the liver displays primarily a hyperplastic response
while an atropic response is exhibited by the thymus.
Factors such as receptor subpopulations, translocation
and receptor binding to DNA may influence the
differential expression of various gene products. Cyto-
plasmic Ah receptor levels of relative binding affinities
are similar for the liver and thymus. However, the
quantity of receptor translocated to the nucleus follow-
ing TCDD challenge is several fold greater in the liver
than thymus although possible tissue differences in
DNA binding sites have not been investigated.
The binding affinity and concentration of hepatic
cytosolic receptor are similar for guinea pig, rat, C57B
mice, rabbit and hamster, yet there exists a 5000-fold
difference in LD50 values for TCDD between guinea pig
and hamster. Comparisons of cytosolic liver receptor
concentrations may not be an adequate indicator of
potential TCDD toxicity but rather nuclear TCDD
receptor interactions may explain the mechanism of
TCDD toxicity.
Summary and Conclusion
The proposed model for the mechanism of action of
TCDD and related compounds was derived from models
for steroid-hormone receptors (Fig. 1). TCDD enters
the celland bindswithhigh affinitytotheAhreceptor(s)
in the cytoplasm. This receptor is selective for TCDD
and related compounds; i.e., it does not bind steroid
hormones or other compounds that do not produce the
spectrum of biochemical and histopathological effects
characteristic ofTCDD exposure. The Ah receptor has
a finite capacity (fmole/mg cytosol protein) which leads
to saturation at low concentrations of ligand allowing
maximal responses at low doses. It is thought that the
TCDD receptor complex translocates to the nucleus
where it binds to specific sites on chromatin thereby
modulating gene expression- producing induction and/or
repression of synthesis of critical macromolecules.
FIGURE 1. Model for mechanism of action of TCDD and related
compounds.
However, little is known about the nuclear translocation
and binding process.
This model is attractive in its simplicity but un-
fortunately it does not provide a unifying hypothesis for
all biochemical and toxic effects associated with ex-
posure to TCDD. For example, there are huge species
variations in susceptibility to hepatic enzyme induction,
lethality and histopathologic effects in spite of the
presence and similarity of properties of receptor in
these species. In other words, the correlations that
exist between cytosolic receptor concentrations and
toxicity ininbred strains ofmice are not presentin other
species. Moreover, species differences in metabolic and
clearance rates are relatively small and cannot account
for species variations to toxicity. These findings suggest
that a primary factor in determining toxicity might be
tissue and species specific factors that control the
actionsofreceptorintargettissues. There are numerous
possible mechanisms that might be involved. For
example, a critical step in receptor action might be
nuclear translocation rates, the location ofbinding sites
for the TCDD-receptor complex on DNA, or tissue and
species specific control over the biochemical events that
control gene expression following nuclear binding.
Alternatively, there may be more than one receptor,
eachproducing different effects orcompetition ofTCDD
with a possible endogenous ligand and may be im-
portant. Clarifyingthe mechanism(s) forTCDD toxicity
would enhance our ability to predict human health
consequences to toxic halogenated aromatics and help
determine whether the human is a "sensitive" or
"resistant" species. Such information would provide a
more rational basis for risk analysis. For example, if
nuclear occupancy of receptor is the critical or rate-
limiting step, then measurement of TCDD-receptor
complexes in the nucleus would represent the "biologi-
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cally-effective dose' This parameter, coupled with ex-
posure data and toxicity evaluation, would tell us the
dose of TCDD required to estimate a specified risk to
effects such as tumor promotion.
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